Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AML Contender Quizartinib Gains First Approval, In Japan

Jun 20 2019

• By Ian Haydock

Acute myeloid leukemia a 3d-Render — Japan Approval For Quizartinib In AML • Source: Shutterstock

Related Content

Quizartinib Looks Like A Good Drug, ODAC Says, But Needs Another Efficacy Trial Before Approval

May 15 2019

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

Oct 22 2018

Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval

Jun 19 2019

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

Jun 19 2019

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

Mar 29 2019

Related Companies

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

Merck & Co., Inc.

Ambit Biosciences Corporation

Myriad Genetics, Inc.

Roche Holding AG

Chugai Pharmaceutical Co., Ltd.

Additional Topics

Japan Asia Pacific Approvals Commercial Cancer BioPharmaceutical

More from Japan

More from Focus On Asia

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window